Source link : https://www.newshealth.biz/health-news/novel-drug-maintained-clinical-improvements-in-ibd/
Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody tulisokibart continued to maintain clinical and endoscopic improvements through week 50, according to data from open-label extensions of a pair of phase II trials. In patients with ulcerative colitis, 48% of those receiving 250 mg of intravenous tulisokibart achieved clinical remission […]
Author : News Health
Publish date : 2024-10-16 17:18:43
Copyright for syndicated content belongs to the linked Source.